Skip to main content
. 2021 May 3;8(2):e000891. doi: 10.1136/jitc-2020-000891

Figure 2.

Figure 2

Progression-free survival and duration of response per independent radiology review committee. (A, B) In intermediate-risk/poor-risk patients. (C, D) In intent-to-treat patients. (E, F) In favorable-risk patients. mDOR, median duration of response; mPFS, median progression-free survival; NE, not estimable; NIVO+IPI, nivolumab plus ipilimumab; NR, not reached; SUN, sunitinib.